Showing results (141-150 of 199) with videos related to
Sort By:
Pageof 20
European Journal of Haematology|October 22, 2020
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature reviewTamir Shragai, Moshe Gatt, Noa Lavie, et al.Haematologica|October 6, 2022
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trialNathalie Asherie, Shlomit Kfir-Erenfeld, Batia Avni, et al.Haematologica|February 12, 2026
ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot studyGil Fridberg, Odelia Amit, Yehonathan Sherf, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2022
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL AmyloidosisShlomit Kfir-Erenfeld, Nathalie Asherie, Sigal Grisariu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2015
Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus MeetingMichael Lishner, Irit Avivi, Jane F Apperley, et al.Leukemia Research|March 5, 2018
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcomeChezi Ganzel, Ory Rouvio, Irit Avivi, et al.Hematological Oncology|April 7, 2026
The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non-Secretory Relapse-A Retrospective Cohort StudyIuliana Vaxman, Itai Zamir, Inbar Cohen, et al.Aging Cell|May 7, 2019
Depletion of B cells rejuvenates the peripheral B-cell compartment but is insufficient to restore immune competence in agingIrit Avivi, Simona Zisman-Rozen, Shulamit Naor, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2014
Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB studyAntonio Salar, Irit Avivi, Beate Bittner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2013
The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myelomaAmnon Peled, Michal Abraham, Irit Avivi, et al.Pageof 20